Home > Archive>Volume 12, Issue 10, 2019 >1555-1560. DOI:10.18240/ijo.2019.10.06
HTML XML Export Cite reminder
Changes of tear film lipid layer thickness by 3% diquafosol ophthalmic solutions in patients with dry eye syndrome
Author:
Corresponding Author:

Kook Young Kim. Department of Ophthalmology, Kim’s Eye Hospital, Myung-Gok Eye Research Institute, Konyang University, #156 Youngdeungpo-dong 4ga, Youngdeungpo-gu, Seoul 150-034, Korea. md.kookyoung@gmail.com

  • Article
    • | |
  • Metrics
    • |
  • Reference [36]
    • |
  • Related
    • | | |
  • Comments
    Abstract:

    AIM: To evaluate the quantitatively changes in lipid layer thickness (LLT) when 3% diquafosol eye drop is used for dry eye patients using the tear film interferometer. METHODS: A total 124 participants (32 males, 92 females; mean age, 28.9y) diagnosed with dry eye disease (DED) received topical instillation of 4 ophthalmic solutions in one eye: diquafosol, normal saline, 0.1% sodium hyaluronate and 0.3% gatifloxacin, in a masked manner. LLT was measured using an interferometer at baseline and 20min after the instillation of each ophthalmic solutions. RESULTS: Changes of LLT after instillation (nm, mean± standard error) were as follows: 12.6±2.0 for diquafosol (P<0.001), 1.2±2.2 for normal saline (P=0.301), 1.5±2.0 for hyaluronate (P=0.495), and 0.5±3.2 for gatifloxacin (P=0.884). CONCLUSION: Topical instillation of diquafosol increases tear film LLT in DED patients. Diquafosol 3% eye drop might be effective treatment option of evaporative DED with meibomian gland dysfunction.

    Reference
    1 Stapleton F, Alves M, Bunya VY, Jalbert I, Lekhanont K, Malet F, Na KS, Schaumberg D, Uchino M, Vehof J, Viso E, Vitale S, Jones L. TFOS DEWS II Epidemiology Report. Ocul Surf 2017;15(3):334-365.
    2 Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo CK, Liu ZG, Nelson JD, Nichols JJ, Tsubota K, Stapleton F. TFOS DEWS II definition and classification report. Ocul Surf 2017;15(3):276-283.
    3 Kobashi H, Kamiya K, Sambe T, Nakagawa R. Factors influencing subjective symptoms in dry eye disease. Int J Ophthalmol 2018;11(12): 1926-1931.
    4 Koh S, Ikeda C, Takai Y, Watanabe H, Maeda N, Nishida K. Long-term results of treatment with diquafosol ophthalmic solution for aqueous-deficient dry eye. Jpn J Ophthalmol 2013;57(5):440-446.
    5 Koh S, Maeda N, Ikeda C, Oie Y, Soma T, Tsujikawa M, Watanabe H, Nishida K. Effect of diquafosol ophthalmic solution on the optical quality of the eyes in patients with aqueous-deficient dry eye. Acta Ophthalmol 2014;92(8):e671-e675.
    6 Murakami T, Fujihara T, Horibe Y, Nakamura M. Diquafosol elicits increases in net Cl-transport through P2Y2 receptor stimulation in rabbit conjunctiva. Ophthalmic Res 2004;36(2):89-93.
    7 Keating GM. Diquafosol ophthalmic solution 3%: a review of its use in dry eye. Drugs 2015;75(8):911-922.
    8 Tauber J, Davitt WF, Bokosky JE, Nichols KK, Yerxa BR, Schaberg AE, LaVange LM, Mills-Wilson MC, Kellerman DJ. Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye. Cornea 2004;23(8):784-792.
    9 Cowlen MS, Zhang VZ, Warnock L, Moyer CF, Peterson WM, Yerxa BR. Localization of ocular P2Y2 receptor gene expression by in situ hybridization. Exp Eye Res 2003;77(1):77-84.
    10 Tanioka H, Kuriki Y, Sakamoto A, Katsuta O, Kawazu K, Nakamura M. Expression of the P2Y₂ receptor on the rat ocular surface during a 1-year rearing period. Jpn J Ophthalmol 2014;58(6):515-521.
    11 Isreb MA, Greiner JV, Korb DR, Glonek T, Mody SS, Finnemore VM, Reddy CV. Correlation of lipid layer thickness measurements with fluorescein tear film break-up time and Schirmer’s test. Eye(Lond) 2003;17(1):79-83.
    12 Korb DR, Baron DF, Herman JP, Finnemore VM, Exford JM, Hermosa JL, Leahy CD, Glonek T, Greiner JV. Tear film lipid layer thickness as a function of blinking. Cornea 1994;13(4):354-359.
    13 Kim JS, Lee H, Choi S, Kim EK, Seo KY, Kim TI. Assessment of the tear film lipid layer thickness after cataract surgery. Semin Ophthalmol 2018;33(2):231-236.
    14 Eom Y, Lee JS, Kang SY, Kim HM, Song JS. Correlation between quantitative measurements of tear film lipid layer thickness and meibomian gland loss in patients with obstructive meibomian gland dysfunction and normal controls. Am J Ophthalmol 2013;155(6):1104-1110.e2.
    15 Hosaka E, Kawamorita T, Ogasawara Y, Nakayama N, Uozato H, Shimizu K, Dogru M, Tsubota K, Goto E. Interferometry in the evaluation of precorneal tear film thickness in dry eye. Am J Ophthalmol 2011;151(1):18-23.e1.
    16 Kim HM, Eom Y, Song JS. The relationship between morphology and function of the meibomian glands. Eye Contact Lens 2018;44(1):1-5.
    17 Korb DR. The tear film: structure, function, and clinical examination. Elsevier Health Sciences, 2002.
    18 Li Y, Kuang K, Yerxa B, Wen Q, Rosskothen H, Fischbarg J. Rabbit conjunctival epithelium transports fluid, and P2Y2(2) receptor agonists stimulate Cl(-) and fluid secretion. Am J Physiol , Cell Physiol 2001;281(2):C595-C602.
    19 Jumblatt JE, Jumblatt MM. Regulation of ocular mucin secretion by P2Y2 nucleotide receptors in Rabbit and human conjunctiva. Exp Eye Res 1998;67(3):341-346.
    20 Murakami T, Fujihara T, Nakamura M, Nakata K. P2Y(2) receptor elicits PAS-positive glycoprotein secretion from Rabbit conjunctival goblet cells in vivo. J Ocul Pharmacol Ther 2003;19(4):345-352.
    21 Pendergast W, Yerxa BR, Douglass JG 3rd, Shaver SR, Dougherty RW, Redick CC, Sims IF, Rideout JL. Synthesis and P2Y receptor activity of a series of uridine dinucleoside 5’-polyphosphates. Bioorg Med Chem Lett 2001;11(2):157-160.
    22 Fujihara T, Murakami T, Nagano T, Nakamura M, Nakata K. INS365 suppresses loss of corneal epithelial integrity by secretion of mucin-like glycoprotein in a Rabbit short- term dry eye model. J Ocul Pharmacol Ther 2002;18(4):363-370.
    23 Yokoi N, Kato H, Kinoshita S. Facilitation of tear fluid secretion by 3% diquafosol ophthalmic solution in normal human eyes. Am J Ophthalmol 2014;157(1):85-92.e1.
    24 Matsumoto Y, Ohashi Y, Watanabe H, Tsubota K, Diquafosol Ophthalmic Solution Phase Study Group. Efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome: a Japanese phase 2 clinical trial. Ophthalmology 2012;119(10):1954-1960.
    25 Takamura E, Tsubota K, Watanabe H, Ohashi Y; Diquafosol Ophthalmic Solution Phase Study Group. A randomised, double-masked comparison study of diquafosol versus sodium hyaluronate ophthalmic solutions in dry eye patients. Br J Ophthalmol 2012;96(10):1310-1315.
    26 Shimazaki-Den S, Iseda H, Dogru M, Shimazaki J. Effects of diquafosol sodium eye drops on tear film stability in short BUT type of dry eye. Cornea 2013;32(8):1120-1125.
    27 Yokoi N, Sonomura Y, Kato H, Komuro A, Kinoshita S. Three percent diquafosol ophthalmic solution as an additional therapy to existing artificial tears with steroids for dry-eye patients with Sjögren’s syndrome. Eye(Lond) 2015;29(9):1204-1212.
    28 Chhadva P, Goldhardt R, Galor A. Meibomian gland disease: the role of gland dysfunction in dry eye disease. Ophthalmology 2017;124(11S): S20-S26.
    29 Nelson JD, Shimazaki J, Benitez-del-Castillo JM, Craig JP, McCulley JP, Den S, Foulks GN. The international workshop on meibomian gland dysfunction: report of the definition and classification subcommittee. Invest Ophthalmol Vis Sci 2011;52(4):1930-1937.
    30 Arita R, Suehiro J, Haraguchi T, Maeda S, Maeda K, Tokoro H, Amano S. Topical diquafosol for patients with obstructive meibomian gland dysfunction. Br J Ophthalmol 2013;97(6):725-729.
    31 Fukuoka S, Arita R. Increase in tear film lipid layer thickness after instillation of 3% diquafosol ophthalmic solution in healthy human eyes. Ocul Surf 2017;15(4):730-735.
    32 McCann LC, Tomlinson A, Pearce EI, Diaper C. Tear and meibomian gland function in blepharitis and normals. Eye Contact Lens 2009;35(4):203-208.
    33 Fujihara T, Murakami T, Fujita H, Nakamura M, Nakata K. Improvement of corneal barrier function by the P2Y(2) agonist INS365 in a rat dry eye model. Invest Ophthalmol Vis Sci 2001;42(1):96-100.
    34 Shigeyasu C, Hirano S, Akune Y, Yamada M. Diquafosol tetrasodium increases the concentration of mucin-like substances in tears of healthy human subjects. Curr Eye Res 2015;40(9):878-883.
    35 Yeon DY, Kang BR, Eom YS, Kim HM, Song JS. The effect of 3% diquafosol tetrasodium on corneal wetting property and mucin-5AC concentration in rabbits. J Korean Ophthalmol Soc 2016;57(2):208.
    36 Li Y, Sang X, Yang L, Wang XR, Liu JH, He XJ, Liu Y, Lu XH, Wang ZC. Low concentration of sodium hyaluronate temporarily elevates the tear film lipid layer thickness in dry eye patients with lipid deficiency. Int J Ophthalmol 2018;11(3):389-394.
    Related
    Cited by
Get Citation

Dong-Hyun Kang, Yong-Woo Lee, Kyu-Yeon Hwang,/et al.Changes of tear film lipid layer thickness by 3% diquafosol ophthalmic solutions in patients with dry eye syndrome. Int J Ophthalmol, 2019,12(10):1555-1560

Copy
Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
Publication History
  • Received:June 08,2018
  • Revised:December 17,2018
  • Online: October 18,2019
You are the  Visitors
Governing Body：Department of Health, Provincial Government of Shaanxi, China
Organizer：Xi'an Medical Association of China
Address：Room 11707-08, Building 2, Unit 1, Wanda Plaza, No.8 Yanta North Road, Xi'an 710054, Shaanxi Province, China
Fax：(8629)82245172 Phone：(+8629)82245172/82210956
Email：ijopress@163.com
International Journal of Ophthalmology ® 2025 All Rights Reserved   The terms of CC BY-NC-ND 4.0 are applicable to all open access content.